Polo-like Kinase 1 (Plk1) Inhibits p53 Function by Physical Interaction and Phosphorylation*

Polo-like kinase 1 (Plk1) has an important role in the regulation of M phase of the cell cycle. In addition to its cell cycle-regulatory function, Plk1 has a potential role in tumorigenesis. Here we found for the first time that Plk1 physically binds to the tumor suppressor p53 in mammalian cultured cells, and inhibits its transactivation activity as well as its pro-apoptotic function. During the cisplatin-induced apoptosis in human neuroblastoma SH-SY5Y cells, the expression level of Plk1 was significantly decreased both at mRNA and protein levels, whereas cisplatin treatment caused a remarkable stabilization of p53. Systematic immunoprecipitation analyses using a series of deletion mutants of p53 revealed that a sequence-specific DNA-binding region of p53 is required and sufficient for the physical interaction with Plk1. The ectopically overexpressed Plk1 was co-localized with the endogenous p53 in mammalian cell nucleus, as shown by confocal laser microscopy. Expression of exogenous Plk1 and p53 in p53-deficient lung carcinoma H1299 cells greatly decreased the p53-mediated transcription from the p53-responsive p21WAF1, MDM2, and BAX promoters, whereas the kinase-deficient mutant form of Plk1 failed to reduce the transcriptional activity of p53. Consistent with the luciferase reporter analysis, Plk1 had an ability to block the p53-dependent induction of the endogenous p21WAF1. In addition, Plk1 inhibited the pro-apoptotic function of p53 in H1299 cells. Intriguingly, Plk1-mediated repression of p53 was attenuated with ATM. Thus, our present findings strongly suggest that p53 is a critical target of Plk1, and its function is abrogated through the physical interaction with Plk1.

[1]  Yoichi Taya,et al.  DNA Damage-Induced Phosphorylation of p53 Alleviates Inhibition by MDM2 , 1997, Cell.

[2]  E. Nishida,et al.  Nuclear Translocation of Plk1 Mediated by Its Bipartite Nuclear Localization Signal* , 2002, The Journal of Biological Chemistry.

[3]  D. Longo,et al.  Cloning and characterization of human and murine homologues of the Drosophila polo serine-threonine kinase. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[4]  A. Wilks,et al.  Identification and cloning of a protein kinase-encoding mouse gene, Plk, related to the polo gene of Drosophila. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[5]  D. Longo,et al.  Polo-like Kinase Is a Cell Cycle-regulated Kinase Activated during Mitosis (*) , 1995, The Journal of Biological Chemistry.

[6]  J. Yuan,et al.  Polo-like kinase, a novel marker for cellular proliferation. , 1997, The American journal of pathology.

[7]  Yoichi Taya,et al.  ATM associates with and phosphorylates p53: mapping the region of interaction , 1999, Nature Genetics.

[8]  T. Karn,et al.  Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Cell cycle- and terminal differentiation-associated regulation of the mouse mRNA encoding a conserved mitotic protein kinase. , 1993 .

[10]  D. Glover,et al.  Polo kinase: the choreographer of the mitotic stage? , 1996, The Journal of cell biology.

[11]  P. Friedman,et al.  Wild-type p53 activates transcription in vitro , 1992, Nature.

[12]  E. Nishida,et al.  Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase , 2001, Nature.

[13]  E. Nishida,et al.  Plk1 promotes nuclear translocation of human Cdc25C during prophase , 2002, EMBO reports.

[14]  V. Rotter,et al.  Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis , 1990, Molecular and cellular biology.

[15]  D. Longo,et al.  Cell Cycle Regulation of the Human Polo-like Kinase (PLK) Promoter* , 1997, The Journal of Biological Chemistry.

[16]  C. Prives,et al.  The p53 pathway , 1999, The Journal of pathology.

[17]  Min Gyu Lee,et al.  Glucose Metabolism in Cancer , 2003, Journal of Biological Chemistry.

[18]  Jürgen Bereiter-Hahn,et al.  Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. , 2002, Journal of the National Cancer Institute.

[19]  D. Slamon,et al.  prk, a Cytokine-inducible Human Protein Serine/Threonine Kinase Whose Expression Appears to be Down-regulated in Lung Carcinomas* , 1996, The Journal of Biological Chemistry.

[20]  Takao Hayakawa,et al.  Autoinhibitory Regulation of p73 by ΔNp73 To Modulate Cell Survival and Death through a p73-Specific Target Element within the ΔNp73 Promoter , 2002, Molecular and Cellular Biology.

[21]  J. Winkles,et al.  Identification by Targeted Differential Display of an Immediate Early Gene Encoding a Putative Serine/Threonine Kinase(*) , 1995, The Journal of Biological Chemistry.

[22]  U. Moll,et al.  ΔNp73, A Dominant-Negative Inhibitor of Wild-type p53 and TAp73, Is Up-regulated in Human Tumors , 2002, The Journal of experimental medicine.

[23]  H. Lane,et al.  Cell-cycle control: POLO-like kinases join the outer circle. , 1997, Trends in cell biology.

[24]  E. Nishida,et al.  Identification of a Consensus Motif for Plk (Polo-like Kinase) Phosphorylation Reveals Myt1 as a Plk1 Substrate* , 2003, Journal of Biological Chemistry.

[25]  David J Weber,et al.  Inhibition of p53 Transcriptional Activity by the S100B Calcium-binding Protein* , 2001, The Journal of Biological Chemistry.

[26]  W. Dai,et al.  Reactive Oxygen Species-induced Phosphorylation of p53 on Serine 20 Is Mediated in Part by Polo-like Kinase-3* , 2001, The Journal of Biological Chemistry.

[27]  Stephen N. Jones,et al.  Regulation of p53 stability by Mdm2 , 1997, Nature.

[28]  F. Kashanchi,et al.  Phosphorylation of p53 Serine 15 Increases Interaction with CBP* , 1998, The Journal of Biological Chemistry.

[29]  Delin Chen,et al.  Negative Control of p53 by Sir2α Promotes Cell Survival under Stress , 2001, Cell.

[30]  C. Dang,et al.  Nuclear and nucleolar targeting sequences of c-erb-A, c-myb, N-myc, p53, HSP70, and HIV tat proteins. , 1989, The Journal of biological chemistry.

[31]  R. Medema,et al.  Inhibition of Polo-like Kinase-1 by DNA Damage Occurs in an ATM- or ATR-dependent Fashion* , 2001, The Journal of Biological Chemistry.

[32]  C. von Ilberg,et al.  Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. , 1999, Cancer research.

[33]  E. Nigg Polo-like kinases: positive regulators of cell division from start to finish. , 1998, Current opinion in cell biology.

[34]  Xiaoqi Liu,et al.  Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Y Taya,et al.  Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. , 1998, Science.

[36]  Guillermina Lozano,et al.  Pirh2, a p53-Induced Ubiquitin-Protein Ligase, Promotes p53 Degradation , 2003, Cell.

[37]  W. Kaelin,et al.  MDM2 Suppresses p73 Function without Promoting p73 Degradation , 1999, Molecular and Cellular Biology.

[38]  R. Erikson,et al.  Mutation of the polo-box disrupts localization and mitotic functions of the mammalian polo kinase Plk. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[39]  C. McGowan,et al.  Mammalian Polo-like kinase 3 (Plk3) is a multifunctional protein involved in stress response pathways , 2002, Oncogene.

[40]  R. Medema,et al.  Polo-like kinase-1 is a target of the DNA damage checkpoint , 2000, Nature Cell Biology.

[41]  A. Bräuninger,et al.  Identification and functional characterization of the human and murine polo-like kinase (Plk) promoter. , 1995, Oncogene.

[42]  Hirofumi Tanaka,et al.  Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 , 1997, FEBS letters.

[43]  R. Mantovani,et al.  The molecular biology of the CCAAT-binding factor NF-Y. , 1999, Gene.

[44]  A. Levine,et al.  Identification of the p53 protein domain involved in formation of the simian virus 40 large T-antigen-p53 protein complex , 1986, Journal of virology.

[45]  J. Bereiter-Hahn,et al.  Cooperative phosphorylation including the activity of polo-like kinase 1 regulates the subcellular localization of cyclin B1 , 2002, Oncogene.

[46]  Kyung S. Lee,et al.  Essential Function of the Polo Box of Cdc5 in Subcellular Localization and Induction of Cytokinetic Structures , 2000, Molecular and Cellular Biology.

[47]  W. Dai,et al.  Plk3 Functionally Links DNA Damage to Cell Cycle Arrest and Apoptosis at Least in Part via the p53 Pathway* , 2001, The Journal of Biological Chemistry.

[48]  B. Vogelstein,et al.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.

[49]  D. Longo,et al.  Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. , 1997, Biochemical and biophysical research communications.

[50]  A. Nakagawara,et al.  Physical Interaction of p73 with c-Myc and MM1, a c-Myc-binding Protein, and Modulation of the p73 Function* , 2002, The Journal of Biological Chemistry.

[51]  Y. Li,et al.  PRK, a cell cycle gene localized to 8p21, is downregulated in head and neck cancer , 2000, Genes, chromosomes & cancer.

[52]  J. Maller,et al.  Purification and cloning of a protein kinase that phosphorylates and activates the polo-like kinase Plx1. , 1998, Science.

[53]  D. Glover,et al.  Polo-like kinases: a team that plays throughout mitosis. , 1998, Genes & development.

[54]  A. Nakagawara,et al.  A product of DAN, a novel candidate tumour suppressor gene, is secreted into culture medium and suppresses DNA synthesis. , 1997, European journal of cancer.

[55]  H. Ackermann,et al.  Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer , 1997, Oncogene.

[56]  K. Vousden Activation of the p53 tumor suppressor protein. , 2002, Biochimica et biophysica acta.

[57]  B. Li,et al.  Human Prk Is a Conserved Protein Serine/Threonine Kinase Involved in Regulating M Phase Functions* , 1997, The Journal of Biological Chemistry.

[58]  E. Nigg,et al.  Cell Cycle Regulation of the Activity and Subcellular Localization of Plk1, a Human Protein Kinase Implicated in Mitotic Spindle Function Finally, Genetic Studies Performed with Fungi and Flies Have Identified Multiple Protein Kinases , 1995 .

[59]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[60]  K. Strebhardt,et al.  PLK (polo‐like kinase), a new prognostic marker for oropharyngeal carcinomas , 2000, International journal of cancer.

[61]  J. Bartek,et al.  Cell cycle analysis and chromosomal localization of human Plk1, a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5. , 1994, Journal of cell science.

[62]  T. Stokke,et al.  Repression of mRNA for the PLK cell cycle gene after DNA damage requires BRCA1 , 2003, Oncogene.

[63]  S. Loibl,et al.  Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells , 2002, Oncogene.

[64]  Chin-Yo Lin,et al.  Functional studies on the role of the C-terminal domain of mammalian polo-like kinase , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[65]  S. Um,et al.  Identification and Characterization of HIPK2 Interacting with p73 and Modulating Functions of the p53 Familyin Vivo * , 2002, The Journal of Biological Chemistry.

[66]  Y. Sánchez,et al.  Incomplete cytokinesis and induction of apoptosis by overexpression of the mammalian polo-like kinase, Plk3. , 2000, Cancer research.